ASCO20: new data suggests feasibility of precision medicine in pediatric cancer

Written by Rachel Jenkins, Future Science Group

Researchers from Hopp Children’s Cancer Center Heidelberg (Germany) have demonstrated the feasibility of precision medicine in pediatric cancer patients who have a poor prognosis. The data was presented at the 2020 annual meeting for the American Society of Clinical Oncology (ASCO; 29–31 May). The INdividualized Therapy FOr Relapsed Malignancies in Childhood (INFORM) registry was developed by pediatric oncologists and genomics researchers to develop precision medicine-based approaches across high-risk relapsed or therapy refractory pediatric cancers. “For pediatric patients, if the cancer has relapsed, the prognosis is poor and there are few new innovative treatments,” commented lead author Cornelis van Tilburg (Hopp...

To view this content, please register now for access

It's completely free